How do you manage bevacizumab-induced TMA that does not improve with drug discontinuation?

Has eculizumab or N acetyl cysteine been used?

Ask a clinical question

Answers grounded in the literature and physician expertise.

Related Questions

Would you offer TPO-RAs to a steroid-refractory chronic ITP patient with history of stroke?

How do you approach deciding which patients with hemophilia B to recommend for gene therapy?

If Ianalumab + eltrombopag (VAYHIT2) gains regulatory approval, what would make you consider its use for second-line therapy after glucocorticoid failure/relapse, given its potential hematologic toxicity?

About Mednet

A community where doctors find answers to medicine's toughest questions.

Verified, credentialed physicians
45,000+ members across 23 specialties
Free CME and MOC credit

Evidence Meets Expertise

Community

Browse Specialties
Code of Conduct
AI Community Guidelines

Tools

Mednet AI
Mobile App

Company

About
Careers
Our Work
Blog

Support

FAQs
Contact Us
Programs

Legal

Privacy Policy
Terms of Service

© 2026 Mednet Inc. All rights reserved.